A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1

  1. Yi Bessie Liu
  2. Ambika Tewari
  3. Johnny Salameh
  4. Elena Arystarkhova
  5. Thomas G Hampton
  6. Allison Brashear
  7. Laurie J Ozelius
  8. Kamran Khodakhah
  9. Kathleen J Sweadner  Is a corresponding author
  1. Harvard Medical School, United States
  2. Albert Einstein College of Medicine, United States
  3. University of Massachusetts Medical School, United States
  4. Mouse Specifics Inc., United States
  5. Wake Forest University School of Medicine, United States

Abstract

A new mutant mouse (lamb1t) exhibits intermittent dystonic hindlimb movements and postures when awake, and hyperextension when asleep. Experiments showed co-contraction of opposing muscle groups, and indicated that symptoms depended on the interaction of brain and spinal cord. SNP mapping and exome sequencing identified the dominant causative mutation in the Lamb1 gene. Laminins are extracellular matrix proteins, widely expressed but also known to be important in synapse structure and plasticity. In accordance, awake recording in the cerebellum detected abnormal output from a circuit of two Lamb1-expressing neurons, Purkinje cells and their deep cerebellar nucleus targets, during abnormal postures. We propose that dystonia-like symptoms result from lapses in descending inhibition, exposing excess activity in intrinsic spinal circuits that coordinate muscles. The mouse is a new model for testing how dysfunction in the CNS causes specific abnormal movements and postures.

Article and author information

Author details

  1. Yi Bessie Liu

    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  2. Ambika Tewari

    Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, United States
    Competing interests
    No competing interests declared.
  3. Johnny Salameh

    Department of Neurology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    No competing interests declared.
  4. Elena Arystarkhova

    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Thomas G Hampton

    Neuroscience Discovery Core, Mouse Specifics Inc., Framingham, United States
    Competing interests
    Thomas G Hampton, owner of the company that has commercialized the gait analysis instrumentation described.
  6. Allison Brashear

    Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, United States
    Competing interests
    Allison Brashear, performs research at Wake Forest with grants from Allergan, Ipsen, and Merz, and has consulting relationships with Allergan and Concerta. Her conflict of interest is managed by Wake Forest School of Medicine.
  7. Laurie J Ozelius

    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  8. Kamran Khodakhah

    Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, United States
    Competing interests
    No competing interests declared.
  9. Kathleen J Sweadner

    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    For correspondence
    sweadner@helix.mgh.harvard.edu
    Competing interests
    No competing interests declared.

Ethics

Animal experimentation: All animal research followed the NRC Guide for the Care and Use of Laboratory Animals and the policies of the Massachusetts General Hospital or Albert Einstein College of Medicine: MGH IACUC approved protocol 2011N000108, and Albert Einstein approved protocol 20130801.

Copyright

© 2015, Liu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,905
    views
  • 403
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yi Bessie Liu
  2. Ambika Tewari
  3. Johnny Salameh
  4. Elena Arystarkhova
  5. Thomas G Hampton
  6. Allison Brashear
  7. Laurie J Ozelius
  8. Kamran Khodakhah
  9. Kathleen J Sweadner
(2015)
A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1
eLife 4:e11102.
https://doi.org/10.7554/eLife.11102

Share this article

https://doi.org/10.7554/eLife.11102

Further reading

    1. Neuroscience
    Ana Maria Ichim, Harald Barzan ... Raul Cristian Muresan
    Review Article

    Gamma oscillations in brain activity (30–150 Hz) have been studied for over 80 years. Although in the past three decades significant progress has been made to try to understand their functional role, a definitive answer regarding their causal implication in perception, cognition, and behavior still lies ahead of us. Here, we first review the basic neural mechanisms that give rise to gamma oscillations and then focus on two main pillars of exploration. The first pillar examines the major theories regarding their functional role in information processing in the brain, also highlighting critical viewpoints. The second pillar reviews a novel research direction that proposes a therapeutic role for gamma oscillations, namely the gamma entrainment using sensory stimulation (GENUS). We extensively discuss both the positive findings and the issues regarding reproducibility of GENUS. Going beyond the functional and therapeutic role of gamma, we propose a third pillar of exploration, where gamma, generated endogenously by cortical circuits, is essential for maintenance of healthy circuit function. We propose that four classes of interneurons, namely those expressing parvalbumin (PV), vasointestinal peptide (VIP), somatostatin (SST), and nitric oxide synthase (NOS) take advantage of endogenous gamma to perform active vasomotor control that maintains homeostasis in the neuronal tissue. According to this hypothesis, which we call GAMER (GAmma MEdiated ciRcuit maintenance), gamma oscillations act as a ‘servicing’ rhythm that enables efficient translation of neural activity into vascular responses that are essential for optimal neurometabolic processes. GAMER is an extension of GENUS, where endogenous rather than entrained gamma plays a fundamental role. Finally, we propose several critical experiments to test the GAMER hypothesis.

    1. Medicine
    2. Neuroscience
    LeYuan Gu, WeiHui Shao ... HongHai Zhang
    Research Article

    The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.